ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,930.85
      1.09%
      US Tech 100
      20,836.00
      1.31%
      Dow Jones
      42,840.26
      1.18%
      Brent Oil
      72.72
      0.00%
      Bitcoin
      97,130.71
      -0.08%
      Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Design Therapeutics Inc (DSGN) Quote

      Design Therapeutics Inc

      Design Therapeutics Inc (DSGN)

      NASDAQ
      6.25
      0.26
      (4.34%)
      Closed December 22 4:00PM
      Delayed by 15 minutes
      6.25
      0.00
      (0.00%)
      After Hours: 6:34PM
      Delayed by 15 minutes

      Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

      Premium

      Key stats and details

      Current Price
      6.25
      Bid
      5.25
      Ask
      7.50
      Volume
      578,167
      5.86 Day's Range 6.38
      2.245 52 Week Range 7.77
      Market Cap
      353.881M
      Previous Close
      5.99
      Open
      5.99
      Last Trade
      795
      @
      6.25
      (priorref)
      Last Trade Time
      Financial Volume
      $ 3,503,000
      VWAP
      6.0588
      Average Volume (3m)
      168,361
      Shares Outstanding
      56,621,037
      Dividend Yield
      -
      PE Ratio
      -5.29
      Earnings Per Share (EPS)
      -1.18
      Revenue
      -
      Net Profit
      -66.86M

      About Design Therapeutics Inc

      Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is a pioneering novel small-molecule therapeutic candidate, called gene-targeted chimera, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases. Design Therapeutics Inc is a preclinical-stage biopharmaceutical company. It is a pioneering novel small-molecule therapeutic candidate, called gene-targeted chimera, that are designed to be disease-modifying and target the underlying cause of inherited nucleotide repeat expansion diseases.

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.designtx.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Design Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker DSGN. The last closing price for Design Therapeutics was $5.99. Over the last year, Design Therapeutics shares have traded in a share price range of $ 2.245 to $ 7.77.

      Design Therapeutics currently has 56,621,037 shares outstanding. The market capitalization of Design Therapeutics is $339.16 million. Design Therapeutics has a price to earnings ratio (PE ratio) of -5.29.

      Ask ADVFN Intelligence (AI)

      DSGN Latest News

      More News

      Form 4 - Statement of changes in beneficial ownership of securities

      December 19 2024
      Edgar (US Regulatory)

      Design Therapeutics to Participate in Multiple Upcoming Investor Conferences

      CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic...

      November 13 2024
      GlobeNewswire Inc.

      Form 8-K - Current report

      November 07 2024
      Edgar (US Regulatory)

      Design Therapeutics Announces Third Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTACTM Portfolio

      Fuchs Endothelial Corneal Dystrophy (FECD) Phase 1 Trial Initiated with Data Expected in the First Half of 2025 Friedreich Ataxia (FA) Program on Track to Initiate Phase 1 Single Ascending Dose...

      November 07 2024
      GlobeNewswire Inc.

      Design Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

      CARLSBAD, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today...

      September 10 2024
      GlobeNewswire Inc.

      Form 4 - Statement of changes in beneficial ownership of securities

      August 12 2024
      Edgar (US Regulatory)

      Form 144 - Report of proposed sale of securities

      August 09 2024
      Edgar (US Regulatory)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      August 05 2024
      Edgar (US Regulatory)

      Form 8-K - Current report

      August 05 2024
      Edgar (US Regulatory)

      Design Therapeutics Announces Second Quarter 2024 Financial Results and Reviews Near-term Milestones for GeneTAC™ Portfolio

      Friedreich Ataxia (FA) and Fuchs Endothelial Corneal Dystrophy (FECD) Programs on Track and Advancing Toward Clinical Trials Active Research Pipeline with Programs Progressing in Myotonic...

      August 05 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10.1452.37510237516.1056.455.162701866.01331725CS
      40.6912.41007194245.567.055.161863556.21949572CS
      120.7613.84335154835.497.774.4851683615.85073822CS
      262.6875.07002801123.577.773.152163405.22315561CS
      523.61136.7424242422.647.772.2452366014.23723167CS
      156-9.74-60.913070669215.9926.31.943463227.00130852CS
      260-21.75-77.678571428628501.943079098.44548504CS

      DSGN - Frequently Asked Questions (FAQ)

      What is the current Design Therapeutics share price?
      The current share price of Design Therapeutics is $ 6.25
      How many Design Therapeutics shares are in issue?
      Design Therapeutics has 56,621,037 shares in issue
      What is the market cap of Design Therapeutics?
      The market capitalisation of Design Therapeutics is USD 339.16M
      What is the 1 year trading range for Design Therapeutics share price?
      Design Therapeutics has traded in the range of $ 2.245 to $ 7.77 during the past year
      What is the PE ratio of Design Therapeutics?
      The price to earnings ratio of Design Therapeutics is -5.29
      What is the reporting currency for Design Therapeutics?
      Design Therapeutics reports financial results in USD
      What is the latest annual profit for Design Therapeutics?
      The latest annual profit of Design Therapeutics is USD -66.86M
      What is the registered address of Design Therapeutics?
      The registered address for Design Therapeutics is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
      What is the Design Therapeutics website address?
      The website address for Design Therapeutics is www.designtx.com
      Which industry sector does Design Therapeutics operate in?
      Design Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      MYSZMy Size Inc
      $ 4.2001
      (211.12%)
      		121.03M
      NVNINVNI Group Ltd
      $ 8.26
      (209.36%)
      		78.06M
      TPICTPI Composites Inc
      $ 2.45
      (100.82%)
      		34M
      ICGIntchains Group Ltd
      $ 8.77
      (88.60%)
      		527.94k
      HSDTHelius Medical Technologies Inc
      $ 0.884851
      (84.34%)
      		121.95M
      CYNCYNGN Inc
      $ 0.4603
      (-71.41%)
      		27.5M
      MTEMMolecular Templates Inc
      $ 0.1502
      (-57.09%)
      		8.63M
      PRFXPainReform Ltd
      $ 5.15
      (-53.85%)
      		2.84M
      GALTGalectin Therapeutics Inc
      $ 1.03
      (-48.50%)
      		8.58M
      BCABBioAtla Inc
      $ 0.6923
      (-41.82%)
      		5.96M
      EDBLEdible Garden AG Inc
      $ 0.24
      (65.06%)
      		354.32M
      APTOAptose Biosciences Inc
      $ 0.28
      (64.51%)
      		305.1M
      TNXPTonix Pharmaceuticals Holding Corporation
      $ 0.606999
      (6.49%)
      		292.16M
      NVDANVIDIA Corporation
      $ 134.70
      (3.08%)
      		287.21M
      PLTRPalantir Technologies Inc
      $ 80.55
      (8.54%)
      		277.63M

      DSGN Discussion

      View Posts
      Monksdream Monksdream 4 months ago
      DSGN under $5
      👍️0
      Monksdream Monksdream 8 months ago
      DSGN under $5
      👍️0

      Your Recent History

      NASDAQ
      DSGN
      Design Therapeutics
      Delayed Upgrade Clock

      Go Ad-Free

      Subscribe to Ad free and enjoy an ad-free experience

      No Ads

      Try Now

      Keep the Ads